Marshall Wace, LLP Bio Atla, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 436,489 shares of BCAB stock, worth $266,258. This represents 0.0% of its overall portfolio holdings.

Number of Shares

436,489

Holding current value

$266,258

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.17 - $2.05 $510,692 - $894,802	436,489 New	436,489 $768,000
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $57,636 - $144,317	45,383 New	45,383 $111,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $568,695 - $2.04 Million	247,259 Added 643.87%	285,661 $765,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $241,548 - $422,806	38,402 New	38,402 $316,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $73,670 - $186,078	-34,587 Reduced 38.8%	54,557 $156,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $254,070 - $1.09 Million	58,007 Added 186.3%	89,144 $445,000
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $591,603 - $963,690	31,137 New	31,137 $611,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.4M

Call Options Held

500

Put Options Held

33.5K

Israel Englander Millennium Management LLC | New York, Ny

2.66M
Shares

$1.62 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

2.52M
Shares

$1.54 Million
0.38% of portfolio
Vanguard Group Inc Valley Forge, PA

1.89M
Shares

$1.15 Million
0.0% of portfolio
Morgan Stanley New York, NY

1.86M
Shares

$1.13 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

874K
Shares

$533,186
0.13% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $22.1M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account